Aloe Emodin Inhibits Colon Cancer Cell Migration/angiogenesis by Downregulating MMP-2/9, RhoB and VEGF Via Reduced DNA Binding Activity of NF-κB
Overview
Pharmacology
Authors
Affiliations
Aloe emodin (AE), a natural anthraquinone, is reported to have antiproliferative activity in various cancer cell lines. In this study we analyzed molecular mechanisms involved in the antimigratory and antiangiogenic activity of this hydroxy anthraquinone in colon cancer cell, WiDr. Our results show that a relatively non toxic concentration of AE suppressed the phorbol-12-myristyl-13-acetate (PMA) induced migration and invasion of tumor cells. On analysis for the molecules involved in the migration/invasion, we found AE downregulated mRNA expression and promoter/gelatinolytic activity of Matrix Metalloproteinase (MMP)-2/9, as well as the RhoB expression at gene and protein level. It was also a strong inhibitor of Vascular Endothelial Growth Factor (VEGF) expression, promoter activity and endothelial cell migration/invasion and in vitro angiogenesis. AE suppressed the nuclear translocation and DNA binding of NF-κB, which is an important transcription factor for controlling MMP-2/9 and VEGF gene expression. Taken together these data indicate that AE target multiple molecules responsible for cellular invasion, migration and angiogenesis. Inhibitory effect on angiogenic and metastatic regulatory processes make AE a sensible candidate as a specific blocker of tumor associated events.
Targeting Invasion: The Role of MMP-2 and MMP-9 Inhibition in Colorectal Cancer Therapy.
Shoari A, Ashja Ardalan A, Dimesa A, Coban M Biomolecules. 2025; 15(1).
PMID: 39858430 PMC: 11762759. DOI: 10.3390/biom15010035.
NF-κB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targets.
Bahrami A, Khalaji A, Najafi M, Sadati S, Raisi A, Abolhassani A Eur J Med Res. 2024; 29(1):610.
PMID: 39702532 PMC: 11658081. DOI: 10.1186/s40001-024-02168-w.
Chen H, Kuo C, Chang Y, Tsai D, Lee M, Lee J BMC Cancer. 2024; 24(1):248.
PMID: 38388902 PMC: 10885375. DOI: 10.1186/s12885-024-11986-4.
Choudhury S, Kumar P, Choudhury D Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(6):3585-3616.
PMID: 38019298 DOI: 10.1007/s00210-023-02857-z.
Zhu M, He Q, Wang Y, Duan L, Rong K, Wu Y Front Pharmacol. 2023; 14:1238841.
PMID: 37900162 PMC: 10600456. DOI: 10.3389/fphar.2023.1238841.